Results 101 to 110 of about 44,475 (230)
Cancer Science, EarlyView.BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto +19 more
wiley +1 more source
Cancer Science, EarlyView.While CAFs are produced as a result of education by cancer cells in non‐scirrhous gastric cancer, normal fibroblasts of scirrhous gastric cancer patients are already pre‐conditioned, forming a stromal field for scirrhous gastric cancer. ABSTRACT Scirrhous gastric cancer has aggressive clinical courses and is characterized by dominating cancer ...
Yoshimi Yasukawa +12 more
wiley +1 more source
Cancer Science, EarlyView.An interstitial lung disease model for DXd antibody‐drug conjugates was established in cynomolgus monkeys by weekly dosing of a non‐targeting DXd ADC. Integrated analysis of bronchoalveolar lavage fluid–derived extracellular vesicle proteomics and lung single‐cell RNA sequencing reveals cell‐type‐resolved molecular features of DXd ADC‐related lung ...
Kazuyoshi Kumagai +5 more
wiley +1 more source
KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2‐Dependent MDSC Recruitment
Cancer Science, EarlyView.KPNA2 drives intratumoral MDSC accumulation and immunosuppression in ovarian cancer via the NF‐κB/CCL2/CCR2 axis. Mechanistically, KPNA2 facilitates NF‐κB/p65 nuclear translocation and induces CCL2 transcription, recruiting MDSCs to establish an immunosuppressive microenvironment.
Qingli Li +8 more
wiley +1 more source
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
European Journal of Haematology, EarlyView.ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino +13 more
wiley +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta +14 more
wiley +1 more source
A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer
The FEBS Journal, EarlyView.Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou +4 more
wiley +1 more source
The FEBS Journal, EarlyView.Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma +1 more
wiley +1 more source
Proteolytic remodelling of the extracellular matrix by pericytes
The FEBS Journal, EarlyView.Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard +4 more
wiley +1 more source